Maxi-Fen-10

Description

General Information about Tamoxifen in Belgium

Tamoxifen citrate is a non-steroidal anti-estrogenic drug, widely used in clinical medicine. It is specifically a selective modulator of estrogen receptors of the triphenylethylene family and has both estrogen agonist and antagonist properties. As such, it can act as an estrogen in some tissues while acting as an anti-estrogen in others. In breast tissue, the drug is a potent anti-estrogen and therefore is commonly used in the treatment of estrogen-related breast cancer in women. Tamoxifen citrate was first developed in 1962 by the pharmaceutical company ICI. It was marketed in the United States soon after, but its initial use was for the treatment of female infertility, a purpose for which the drug does not seem ideally suited. It wasn't until 1977 that the FDA approved the drug for use in the United States for the treatment of breast cancer. The drug was sold by ICI in a number of global markets under the Nolvadex brand.

When it comes to its use in steroid users, tamoxifen citrate can help in two ways. Firstly due to the binding affinity of the compound it is able to help in the prevention of gynocomastia. Tamoxifen will compete with estrogen for estrogen receptors in certain tissues, including the breast, and if it can bind to the receptor, estrogen will not have the opportunity to interact with the receptor and therefore gynocomastia should not be able to develop.When using anabolic steroids that can convert to estradiol (estrogen) this protection against gynocomastia can be invaluable. However, it should be noted that tamoxifen citrate will not eliminate estrogen or allow the conversion to occur. Instead, it attempts to counteract the effects of estrogen circulating in the body in the tissues that the drug effects. Therefore, there is no evidence that tamoxifen citrate counteracts etrogenic side effects that are unrelated to tissues other than breast, liver, or bone. Namely there is no real causal link to any reduction in water retention and acne in users who start taking tamoxifen citrate with respect to estrogen. The second, and perhaps more beneficial, aspect of tamoxifen citrate for steroid users is its ability to increase the production of luteinizing hormone and follicle-stimulating hormone, and therefore increase testosterone. This ability is why it is often used by steroid users during their post cycle therapy. There are numerous studies that indicate that tamoxifen citrate can increase levels of these hormones quite drastically. Tamoxifen citrate does this by blocking the negative feedback inhibition caused by estrogen to the hypothalamus and pituitary gland, which in turn will help increase the production of these hormones. Unlike clomiphine citrate, tamoxifen citrate has also been shown to increase luteinizing hormone responsiveness to gonadotropin releasing hormone. Clomiphine citrate may decrease this reactivity over time.One of the possible side effects associated with the use of tamoxifen citrate is the possible reduction in insulin-like growth factor levels. If these levels are reduced it could suppress the gains that a person can make slightly. However, this reduction, if it actually exists, would not be overly significant with muscle mass gains only being marginally reduced for the most part.

Dosage:

When it comes to dosage for fighting gynocomastia that has started to form, there is very little research. The limited research that does exist only points to the fact that doses of 20-40mgs per day are effective in treating the existing condition. However, anecdote users have reported sometimes using doses of 60-80mgs per day. For use during post cycle therapy, users have anecdotally reported that doses between 20-40mg per day are average. These doses have been shown to significantly increase levels of testosterone, luteinizing hormone, and follicle-stimulating hormone.